We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.68 | 0.70% | 97.77 | 97.82 | 96.92 | 97.08 | 182,142 | 15:28:15 |
From Apr 2019 to Apr 2024
By Carlo Martuscelli
Novartis AG (NOVN.EB) said Monday that it will cease development of its investigational asthma drug fevipiprant following disappointing clinical data.
A pooled analysis of the Phase 3 Luster-1 and Luster-2 studies showed that the therapy didn't meet the clinical threshold in the reduction of moderate-to-severe asthma exacerbations when compared with placebo, the company said. The drug was, however, found safe, the Swiss drug maker said.
An analysis of safety and efficacy data from the two studies will be conducted, and details will be published at an upcoming medical conference, Novartis said.
Write to Carlo Martuscelli at carlo.martuscelli@wsj.com; @carlomartu
(END) Dow Jones Newswires
December 16, 2019 01:39 ET (06:39 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
